The use of blood tests, particularly of p-tau217, in the diagnosis of Alzheimer’s disease has taken off in the last few years, with the number of tests being prescribed now doubling every four to six ...

Blood draws from across sub-Saharan Africa are underway. Samples are shipped from Nigeria to Miami. There, their genetics and biomarkers are being analyzed. According to the most recent Global Burden ...

Many people with Alzheimer’s notice their sense of smell isn’t as sharp as it used to be long before their memory declines. The underlying mechanisms responsible for this change have remained a ...

For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical practice. Now, they are on the cusp. At this year’s ADPD conference, held ...

Austria’s beautiful capital city of Vienna hosted the 19th International Conference on Alzheimer’s and Parkinson’s diseases, which drew a record 5,554 attendees from 76 countries. From April 1 to 5, ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

Mivelsiran docks APP products in early AD. Phase 2 trial asks: Can it treat CAA? LX1001 gene therapy boosts CSF ApoE2, stabilizes AD biomarkers. Intranasal insulin quells systemic inflammation. These ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

As amyloid immunotherapy is being rolled out, mostly in specialty care thus far, both treating physicians and researchers have many questions about it. Scientists at the Alzheimer’s Association ...

A new multiplex diagnostic method appears poised to resculpt the biomarker landscape. NULISA, aka NUcleic acid Linked Immunosorbent Assay, can detect Aβ peptides, p-tau isoforms, and other potential ...

For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists argue that people with two APOE4 alleles ...

In Phase 3, HMTM failed to meet co-primary endpoints. Subgroup analysis of an open-label extension suggests benefit in people with MCI. In that subgroup, half as many people transitioned to AD. HMTM ...